• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ZimVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    5/8/25 4:10:42 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care
    Get the next $ZIMV alert in real time by email
    8-K
    false 0001876588 0001876588 2025-05-08 2025-05-08
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 8, 2025

     

     

    ZimVie Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-41242   87-2007795
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)
    4555 Riverside Drive  
    Palm Beach Gardens, FL     33410
    (Address of Principal Executive Offices)     (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (800) 342-5454

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, par value $0.01 per share   ZIMV   The Nasdaq Stock Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 2.02

    Results of Operations and Financial Condition.

    On May 8, 2025, ZimVie Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2025. The press release is attached hereto as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report.

     

    Item 7.01

    Regulation FD Disclosure.

    On May 8, 2025, the Company also made available a presentation that contains supplemental financial information, including full-year 2025 financial guidance. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and the information set forth therein is incorporated herein by reference.

    The information contained in Item 2.02 and Item 7.01 of this report, including Exhibit 99.1 and Exhibit 99.2 hereto, is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

     

    Item 9.01

    Financial Statements and Exhibits.

     

    (d)

    Exhibits

    EXHIBIT INDEX

     

    Exhibit
    No.

      

    Description

    99.1    Press release dated May 8. 2025
    99.2    Presentation dated May 8, 2025
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

          ZimVie Inc.
    Date: May 8, 2025     By:  

    /s/ Heather Kidwell

        Name:   Heather Kidwell
        Title:   Senior Vice President, Chief Legal, Compliance and Human Resources Officer and Corporate Secretary
    Get the next $ZIMV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZIMV

    DatePrice TargetRatingAnalyst
    7/31/2025$19.00Buy → Neutral
    B. Riley Securities
    7/22/2025$19.00Underweight → Equal Weight
    Barclays
    4/10/2025$16.00Buy
    B. Riley Securities
    3/13/2025Buy → Hold
    Needham
    5/16/2024$20.00Hold → Buy
    Needham
    11/16/2023Hold
    Needham
    12/21/2022$9.00Underweight
    Barclays
    6/17/2022$20.00Neutral
    JP Morgan
    More analyst ratings

    $ZIMV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ZimVie Announces Completion of its Acquisition by ARCHIMED

    PALM BEACH GARDENS, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. ("ZimVie"), a global life sciences leader in the dental implant market, today announced that ARCHIMED, an investment firm focused exclusively on healthcare industries, has completed its previously announced acquisition of ZimVie. Pursuant to the terms of the transaction announced on July 20, 2025, ARCHIMED acquired all of the outstanding shares of ZimVie stock. ZimVie stockholders are entitled to receive $19.00 in cash for each share of ZimVie common stock owned. As a result of the transaction completion, ZimVie's common stock no longer trades on the NASDAQ stock exchange. "We are excited to partner with ZimVie to ac

    10/20/25 9:00:28 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie Stockholders Vote to Approve Acquisition by ARCHIMED

    PALM BEACH GARDENS, Fla., Oct. 10, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. ("ZimVie") (NASDAQ:ZIMV) today announced that at the special meeting of ZimVie stockholders held on October 10, 2025, the ZimVie stockholders voted to approve the acquisition of ZimVie by an affiliate of ARCHIMED (the "Merger") pursuant to the terms and conditions of the Agreement and Plan of Merger, dated as of July 20, 2025 (the "Merger Agreement"). The parties now expect the Merger to close on October 20, 2025, subject to the satisfaction of all conditions in the Merger Agreement. About ZimVie ZimVie is a global life sciences leader in the dental implant market that develops, manufactures, and delivers a comprehe

    10/10/25 9:15:00 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie Reports Second Quarter 2025 Financial Results

    Recently entered into definitive agreement to be acquired by ARCHIMED for $19.00 in cash per shareNet Sales from Continuing Operations of $116.7 millionNet Loss from Continuing Operations of $(3.8) million; Net Loss margin of (3.3)% Adjusted EBITDA[1] from Continuing Operations of $17.5 million; Adjusted EBITDA[1] margin of 15.0%GAAP diluted EPS from Continuing Operations of $(0.14) and adjusted diluted EPS[1] from Continuing Operations of $0.26 PALM BEACH GARDENS, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today reported financial results for the quarter ended June 30, 2025. "Our results this quarter ref

    7/30/25 4:05:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by ZimVie Inc.

    SCHEDULE 13G/A - ZimVie Inc. (0001876588) (Subject)

    11/14/25 3:08:24 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ZimVie Inc.

    SCHEDULE 13G/A - ZimVie Inc. (0001876588) (Subject)

    11/13/25 4:53:29 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    SEC Form 15-12G filed by ZimVie Inc.

    15-12G - ZimVie Inc. (0001876588) (Filer)

    10/31/25 10:56:04 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ZIMV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    ZimVie downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded ZimVie from Buy to Neutral and set a new price target of $19.00

    7/31/25 7:17:57 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie upgraded by Barclays with a new price target

    Barclays upgraded ZimVie from Underweight to Equal Weight and set a new price target of $19.00

    7/22/25 10:21:16 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on ZimVie with a new price target

    B. Riley Securities initiated coverage of ZimVie with a rating of Buy and set a new price target of $16.00

    4/10/25 12:44:28 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Officer Kanaglekar Indraneel returned 63,438 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ZimVie Inc. (0001876588) (Issuer)

    10/20/25 5:45:41 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Director Crawford Sally returned 40,127 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ZimVie Inc. (0001876588) (Issuer)

    10/20/25 5:35:06 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Officer Schneider Sandra returned 40,794 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ZimVie Inc. (0001876588) (Issuer)

    10/20/25 5:24:52 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    Financials

    Live finance-specific insights

    View All

    ZimVie Reports Second Quarter 2025 Financial Results

    Recently entered into definitive agreement to be acquired by ARCHIMED for $19.00 in cash per shareNet Sales from Continuing Operations of $116.7 millionNet Loss from Continuing Operations of $(3.8) million; Net Loss margin of (3.3)% Adjusted EBITDA[1] from Continuing Operations of $17.5 million; Adjusted EBITDA[1] margin of 15.0%GAAP diluted EPS from Continuing Operations of $(0.14) and adjusted diluted EPS[1] from Continuing Operations of $0.26 PALM BEACH GARDENS, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today reported financial results for the quarter ended June 30, 2025. "Our results this quarter ref

    7/30/25 4:05:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie to Report Second Quarter 2025 Financial Results on July 30, 2025

    PALM BEACH GARDENS, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced it will report financial results for the second quarter 2025 and file its Quarterly Report on Form 10-Q after market close on Wednesday, July 30, 2025. On July 21, 2025, ZimVie issued a press release announcing ZimVie's entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED ("ARCHIMED") for $19.00 in cash per share. A copy of that press release is accessible by visiting the "Investor Relations" section of ZimVie's website. The transaction is expected to close by year-end 2025, su

    7/25/25 8:00:00 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie Reports First Quarter 2025 Financial Results

    Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2025. Management will host a corresponding conference call today, May 8, 2025, at 4:30 p.m. Eastern Time. "We are proud to have entered 2025

    5/8/25 4:05:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    Leadership Updates

    Live Leadership Updates

    View All

    ZimVie Announces Upcoming Changes to Company's Board of Directors

    PALM BEACH GARDENS, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced upcoming changes to the Company's Board of Directors, including:  Non-Executive Chair David King will not stand for reelection as a director upon the expiration of his current term at the Company's annual meeting of shareholders on May 7, 2025.President and CEO Vafa Jamali will be appointed Chairman of the Board effective as of May 7, 2025.Director Vinit Asar will be appointed Lead Independent Director effective upon the commencement of Mr. Jamali's service as Chairman. Retirement of Mr. King "On behalf of ZimVie and our Boar

    3/13/25 4:15:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Veradigm Announces Board Expansion and Changes

    Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

    2/20/25 4:02:00 PM ET
    $MDRX
    $OCX
    $ZIMV
    EDP Services
    Technology
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ZIMV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ZimVie Inc.

    SC 13G - ZimVie Inc. (0001876588) (Subject)

    11/14/24 4:11:11 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ZimVie Inc.

    SC 13G/A - ZimVie Inc. (0001876588) (Subject)

    11/14/24 10:58:06 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ZimVie Inc.

    SC 13G/A - ZimVie Inc. (0001876588) (Subject)

    10/4/24 1:02:25 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care